Reading GDRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GDRX free→Reading GDRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track GDRX free→NASDAQHealth CareHealth Information ServicesSnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but risk is elevated, and the sector backdrop is a headwind. Peer multiples imply a price about 37% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. The outlook hinges on guidance from GDRX and trends among sector bellwethers like VEEV, BTSG, and TEM. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 6 valuation methods, at three horizons. Current price $2.73. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.73 GDRX trades at 8× p/e, below its 15× p/e peer median. Our $4.33 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 37% below a flat-multiple fair value, below our forecast of about -1%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 8.30x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.08 → $0.08 (-2.6% / 30d). 3 raised, 5 cut, 12 covering analysts.
0 upgrades, 0 downgrades / 30d. 33% of analysts rate Buy.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$270.
How much price usually moves either way.
On a bad day, this stock has moved -$655.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,348.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show how GoodRx is doing in the market.
Confirms one read:Earnings report shows revenue and profit margins are better than expected.
Confirms the other:Earnings report shows revenue and profit margins are worse than expected.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for GDRX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Technology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
GDRX GoodRx Holdings Inc | Above typical Show detailsSector percentile: 85 of 100 | inexpensive | elevated |
VEEV Veeva Systems | Above typical Show detailsSector percentile: 79 of 100 | full | elevated |
SOLV Solventum | Above typical Show detailsSector percentile: 74 of 100 | fair | moderate |
TEM TEMPUS AI, INC. | Above typical Show detailsSector percentile: 72 of 100 | — | elevated |
TXG 10X Genomics, Inc. | Typical Show detailsSector percentile: 46 of 100 | expensive | elevated |
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on sustaining growth and maintaining strong margins as part of the company's strategic direction.
Management aims to achieve an Adjusted EBITDA greater than $235 million for the fiscal year 2026.
Why it matters: If revenue growth picks up, it could signal a positive shift in the sector's maturity phase.
Confirms:Q2 revenue growth speeds up to nearly 10% compared to last year.
Disproves:Q2 revenue growth remains below 10% year over year.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Accounting Officer Appointment On April 23, 2026, the Board of Directors (the “Board”) of GoodRx Holdings, Inc. (the “Company”) appointed Thomas Chan, Vice President, Corporate Controller of the Company as the Company’s Chief Accounting Officer and designated Mr. Chan as the principal accounting officer of the Company, in each case effective…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Departure of Director On March 31, 2026, Ian T. Clark notified GoodRx Holdings, Inc. (the “Company”) of his decision to resign as a member of the Company’s Board of Directors (the “Board“), including his service on the Board’s Nominating & Governance Committee, effective as of March 31, 2026. Mr. Clark has indicated to the Company that his decision…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Chief Accounting Officer Resignation On March 24, 2026, Romin Nabiey submitted his resignation as Chief Accounting Officer of GoodRx Holdings, Inc. (the “Company”), effective April 3, 2026 in order to pursue other opportunities. Mr. Nabiey will remain an employee of the Company through June 8, 2026 to support the transition of his responsibilities…
Changes in Registrant’s Certifying Accountant On March 14, 2026, the Audit and Risk Committee of the Board of Directors of GoodRx Holdings, Inc. (the “Company”), following a competitive proposal process, approved the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the dismissal of PricewaterhouseCoopers LLP (“PwC”) as the Company’s independent registered public accounting firm. The audit…